<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">urovest</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник урологии</journal-title><trans-title-group xml:lang="en"><trans-title>Urology Herald</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2308-6424</issn><publisher><publisher-name>Rostov State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21886/2308-6424-2025-13-1-13-18</article-id><article-id custom-type="elpub" pub-id-type="custom">urovest-1005</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Калькулятор дифференциации гиперплазии и рака предстательной железы</article-title><trans-title-group xml:lang="en"><trans-title>Benign prostate hyperplasia and prostate cancer differentiation calculator</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1710-0169</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коган</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kogan</surname><given-names>M. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Михаил Иосифович Коган — д-р мед. наук, профессор, заслуженный деятель науки РФ</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Mikhail I. Kogan — Dr.Sc.(Med), Full Prof., Hons. Sci. of the Russian Federation</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">dept_kogan@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2733-0619</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ефремов</surname><given-names>М. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Efremov</surname><given-names>M. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Михаил Евгеньевич Ефремов — канд. мед. наук</p><p>Краснодар</p></bio><bio xml:lang="en"><p>Mikhail E. Efremov — Сand.Sc.(Med)</p><p>Krasnodar</p></bio><email xlink:type="simple">efremov.uro@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8335-2578</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Медведев</surname><given-names>В. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Medvedev</surname><given-names>V. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Владимир Леонидович Медведев — д-р мед. наук, профессор</p></bio><bio xml:lang="en"><p>Vladimir L. Medvedev — Dr.Sc. (Med.), Full Prof</p><p>Krasnodar </p></bio><email xlink:type="simple">medvedev_vl@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4120-9180</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Синявская</surname><given-names>Т. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Sinyavskaya</surname><given-names>T. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Татьяна Геннадьевна Синявская — канд. экон. наук, доцент</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Tatiana G. Sinyavskaya — Cand.Sc. (Econ), Assoc.Prof. (Docent)</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">sin-ta@yandex.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Ростовский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rostov State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Кубанский государственный медицинский университет; Научно-исследовательский институт — Краевая клиническая больница № 1 им. проф. С. В. Очаповского</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kuban State Medical University ; Prof. Ochapovsky Research Institute — Krasnodar Regional Clinical Hospital No. 1</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Ростовский государственный экономический университет (РИНХ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rostov State University of Economics (RINH)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>01</day><month>03</month><year>2025</year></pub-date><volume>13</volume><issue>1</issue><fpage>13</fpage><lpage>18</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Коган М.И., Ефремов М.Е., Медведев В.Л., Синявская Т.Г., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Коган М.И., Ефремов М.Е., Медведев В.Л., Синявская Т.Г.</copyright-holder><copyright-holder xml:lang="en">Kogan M.I., Efremov M.E., Medvedev V.L., Sinyavskaya T.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.urovest.ru/jour/article/view/1005">https://www.urovest.ru/jour/article/view/1005</self-uri><abstract><sec><title>Ведение</title><p>Ведение. Дифференциальная диагностика гиперплазии предстательной железы (ГПЖ) и рака предстательной железы (РПЖ) является сложным многоступенчатым процессом. При этом известно, что мужчины с ГПЖ и РПЖ имеют достоверные различия в особенностях сексуальной активности на протяжении жизни.</p></sec><sec><title>Цель исследования</title><p>Цель исследования. Разработать модель прогнозирования рисков РПЖ или ГПЖ с учётом сексуальной активности мужчин и создать на этой основе калькулятор дифференциации РПЖ и ГПЖ.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В открытое проспективное кросс-секциональное несравнительное исследование включены 47 мужчин в возрасте 49 – 71 года с ГПЖ и 87 мужчин в возрасте 47 – 70 лет с впервые установленным диагнозом «РПЖ». У пациентов определяли уровень ПСА сыворотки крови, общего тестостерона, объём предстательной железы. Оценивали результаты опроса по результатам анкеты «Ростовский опросник интегральной оценки мужской сексуальности».</p></sec><sec><title>Результаты</title><p>Результаты. Методики логистической регрессии позволили установить, что прогнозирование ГПЖ или РПЖ возможно на основании уровня сексуальности пациента, объёма предстательной железы и уровня ПСА. При увеличении уровня сексуальности на 1 балл шансы на то, что у пациента будет диагноз «ГПЖ», а не «РПЖ», возрастают в среднем в 1,08 раза. При увеличении объёма ПЖ на 1 см3 шансы выявления ГПЖ возрастают в среднем в 1,15 раза. При увеличении уровня ПСА на 1 нг/мл шансы на ГПЖ по сравнению с РПЖ снижаются в 0,13 раза. На основании результатов математического моделирования разработан калькулятор дифференциации.</p></sec><sec><title>Заключение</title><p>Заключение. Простой калькулятор, представленный в исследовании, имеет чувствительность и специфичность &gt; 0,90 и может быть оценён в предстоящих клинических испытаниях.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Differential diagnosis of benign prostate hyperplasia (BPH) and prostate cancer (PCa) is a complex, multi-stage process. It is known that men with BPH and PCa have significant differences in their sexual activity throughout life.</p></sec><sec><title>Objective</title><p>Objective. To devise a model for predicting the risks of developing PCa or BPH, considering male sexual activity, and to construct a calculator based on this model to distinguish between the two conditions.</p></sec><sec><title>Materials &amp; methods</title><p>Materials &amp; methods. An open prospective non-comparative сross-section study involved 47 men aged 49–71 years with BPH and 87 men aged 47 – 70 years who had been newly diagnosed with PCa. The patients underwent testing for serum PSA levels, total testosterone, and prostate volume. The results of the survey based on the “Rostov Integral Assessment of Male SExuality Questionnaire — RIAMSE” were evaluated.</p></sec><sec><title>Results</title><p>Results. Logistic regression techniques have shown that a patient's sexuality, prostate volume, and PSA level can be predictive of a patient's risk of having either a BPH or an PCa. A 1-point increase in sexuality increases the odds that a patient will be diagnosed with BPH rather than PCa by an average of 1.08 times. If the volume of the PSA increases by 1 cm3, the odds of being diagnosed with BPH increase by an average of 1.15 times. A 1 ng/ml increase in PSA level decreases the odds of detecting BPH compared to PCa by a factor of 0.13. A differentiation calculator was developed based on the results of mathematical modelling.</p></sec><sec><title>Conclusion</title><p>Conclusion. The simple calculator presented in the study has a sensitivity and specificity &gt; 0.90 and can be evaluated in upcoming clinical trials.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рак предстательной железы</kwd><kwd>гиперплазия предстательной железы</kwd><kwd>диагностика</kwd></kwd-group><kwd-group xml:lang="en"><kwd>prostate cancer</kwd><kwd>benign prostate hyperplasia</kwd><kwd>diagnosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Пушкарь Д.Ю., Раснер П.И. Дифференциальная диагностика рака и доброкачественной гиперплазии предстательной железы. РМЖ. 2014;17:1298. eLIBRARY ID: 21846217; EDN: SKBOXD</mixed-citation><mixed-citation xml:lang="en">Pushkar' D.YU., Rasner P.I. Differentsial'naya diagnostika raka i dobrokachestvennoi giperplazii predstatel'noi zhelezy. RMZH. 2014;17:1298. (In Russian). eLIBRARY ID: 21846217; EDN: SKBOXD</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Рак предстательной железы: протеомика, геномика, хирургия. Под ред. Коган М.И., Пушкарь Д.Ю. М.: АБВ-пресс; 2019. ISBN: 978 5 903018 64 2</mixed-citation><mixed-citation xml:lang="en">Rak predstatel'noi zhelezy: proteomika, genomika, khirurgiya. Moskva: ABV-press; 2019. (In Russian). ISBN: 978 5 903018 64 2</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Merriel SWD, Pocock L, Gilbert E, Creavin S, Walter FM, Spencer A, Hamilton W. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med. 2022;20(1):54. DOI: 10.1186/s12916-021-02230-y</mixed-citation><mixed-citation xml:lang="en">Merriel SWD, Pocock L, Gilbert E, Creavin S, Walter FM, Spencer A, Hamilton W. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med. 2022;20(1):54. DOI: 10.1186/s12916-021-02230-y</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Drost FH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. 2019;4(4):CD012663. DOI: 10.1002/14651858.CD012663.pub2</mixed-citation><mixed-citation xml:lang="en">Drost FH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. 2019;4(4):CD012663. DOI: 10.1002/14651858.CD012663.pub2</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Wagaskar VG, Levy M, Ratnani P, Moody K, Garcia M, Pedraza AM, Parekh S, Pandav K, Shukla B, Prasad S, Sobotka S, Haines K, Punnen S, Wiklund P, Tewari A. Clinical Utility of Negative Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer and Clinically Significant Prostate Cancer. Eur Urol Open Sci. 2021;28:9-16. DOI: 10.1016/j.euros.2021.03.008</mixed-citation><mixed-citation xml:lang="en">Wagaskar VG, Levy M, Ratnani P, Moody K, Garcia M, Pedraza AM, Parekh S, Pandav K, Shukla B, Prasad S, Sobotka S, Haines K, Punnen S, Wiklund P, Tewari A. Clinical Utility of Negative Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer and Clinically Significant Prostate Cancer. Eur Urol Open Sci. 2021;28:9-16. DOI: 10.1016/j.euros.2021.03.008</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Коган М.И., Киреев А.Ю. Анкета интегральной оценки мужской сексуальности. Урология. 2009;(1):46-50. eLIBRARY ID: 12162910; EDN: KGEESH</mixed-citation><mixed-citation xml:lang="en">Kogan M.I., Kireev A.Yu. The questionnaire of integral assessment of male sexuality. Urologiia. 2009;(1):46-50. (In Russian). eLIBRARY ID: 12162910; EDN: KGEESH</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Farrell C, Noyes SL, Joslin J, Varma M, Moriarity A, Buchach C, Mammen L, Lane BR. Prostate Multiparametric Magnetic Resonance Imaging Program Implementation and Impact: Initial Clinical Experience in a Community Based Health System. Urol Pract. 2018;5(3):165-171. DOI: 10.1016/j.urpr.2017.03.009</mixed-citation><mixed-citation xml:lang="en">Farrell C, Noyes SL, Joslin J, Varma M, Moriarity A, Buchach C, Mammen L, Lane BR. Prostate Multiparametric Magnetic Resonance Imaging Program Implementation and Impact: Initial Clinical Experience in a Community Based Health System. Urol Pract. 2018;5(3):165-171. DOI: 10.1016/j.urpr.2017.03.009</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A metaanalysis. Ann Oncol. 2015;26(5):848-864. DOI: 10.1093/annonc/mdu525</mixed-citation><mixed-citation xml:lang="en">Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A metaanalysis. Ann Oncol. 2015;26(5):848-864. DOI: 10.1093/annonc/mdu525</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Roobol MJ, Verbeek JFM, van der Kwast T, Kümmerlin IP, Kweldam CF, van Leenders GJLH. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth. Eur Urol. 2017;72(1):45-51. DOI: 10.1016/j.eururo.2017.01.033</mixed-citation><mixed-citation xml:lang="en">Roobol MJ, Verbeek JFM, van der Kwast T, Kümmerlin IP, Kweldam CF, van Leenders GJLH. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth. Eur Urol. 2017;72(1):45-51. DOI: 10.1016/j.eururo.2017.01.033</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Schoots IG, Roobol MJ. Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions. World J Urol. 2020;38(3):517-529. DOI: 10.1007/s00345-019-02707-9</mixed-citation><mixed-citation xml:lang="en">Schoots IG, Roobol MJ. Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions. World J Urol. 2020;38(3):517-529. DOI: 10.1007/s00345-019-02707-9</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Saba K, Wettstein MS, Lieger L, Hötker AM, Donati OF, Moch H, Ankerst DP, Poyet C, Sulser T, Eberli D, Mortezavi A. External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer. J Urol. 2020;203(4):719-726. DOI: 10.1097/JU.0000000000000622</mixed-citation><mixed-citation xml:lang="en">Saba K, Wettstein MS, Lieger L, Hötker AM, Donati OF, Moch H, Ankerst DP, Poyet C, Sulser T, Eberli D, Mortezavi A. External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer. J Urol. 2020;203(4):719-726. DOI: 10.1097/JU.0000000000000622</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Peters M, Eldred-Evans D, Kurver P, Falagario UG, Connor MJ, Shah TT, Verhoeff JJC, Taimen P, Aronen HJ, Knaapila J, Montoya Perez I, Ettala O, Stabile A, Gandaglia G, Fossati N, Martini A, Cucchiara V, Briganti A, Lantz A, Picker W, Haug ES, Nordström T, Tanaka MB, Reddy D, Bass E, van Rossum PSN, Wong K, Tam H, Winkler M, Gordon S, Qazi H, Boström PJ, Jambor I, Ahmed HU. Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging-detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score. Eur Urol. 2022;82(5):559-568. DOI: 10.1016/j.eururo.2022.07.022</mixed-citation><mixed-citation xml:lang="en">Peters M, Eldred-Evans D, Kurver P, Falagario UG, Connor MJ, Shah TT, Verhoeff JJC, Taimen P, Aronen HJ, Knaapila J, Montoya Perez I, Ettala O, Stabile A, Gandaglia G, Fossati N, Martini A, Cucchiara V, Briganti A, Lantz A, Picker W, Haug ES, Nordström T, Tanaka MB, Reddy D, Bass E, van Rossum PSN, Wong K, Tam H, Winkler M, Gordon S, Qazi H, Boström PJ, Jambor I, Ahmed HU. Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging-detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score. Eur Urol. 2022;82(5):559-568. DOI: 10.1016/j.eururo.2022.07.022</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Коган М.И., Ефремов М.Е., Медведев В.Л., Аносов А.Д., Братова А.В. Половая конституция (сексуальность) мужчин с раком предстательной железы. Урология. 2024;(6):56-60. DOI: https://dx.doi.org/10.18565/urology.2024.6.53-60</mixed-citation><mixed-citation xml:lang="en">Kogan M.I., Efremov M.E., Medvedev V.L., Anosov A.D., Bratova A.V. Sexual constitution (sexuality) of men with prostate cancer. Urologiia. 2024;(6):56-60. (In Russian). DOI: https://dx.doi.org/10.18565/urology.2024.6.53-60</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
